Safety and efficacy of reduced-dose pentamidine as second-line treatment for HIV-related pneumocystis pneumonia.

[1]  F. Antunes,et al.  Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  M. Falagas,et al.  Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  Chang-Pan Liu,et al.  Mortality predictors of Pneumocystis jirovecii pneumonia in human immunodeficiency virus-infected patients at presentation: Experience in a tertiary care hospital of northern Taiwan. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[4]  T. Benfield,et al.  Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. , 2009, The Journal of antimicrobial chemotherapy.

[5]  H. Yazaki,et al.  Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Choi,et al.  Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  T. Benfield,et al.  Second-Line Salvage Treatment of AIDS-Associated Pneumocystis jirovecii Pneumonia: A Case Series and Systematic Review , 2008, Journal of acquired immune deficiency syndromes.

[8]  Andrew J Copas,et al.  Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Cappell,et al.  Pentamidine-associated pancreatitis , 1989, Digestive Diseases and Sciences.

[10]  C. Beard,et al.  Current Epidemiology of Pneumocystis Pneumonia , 2004, Emerging infectious diseases.

[11]  R. Wachter,et al.  Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia , 2003, AIDS.

[12]  S. Meshnick,et al.  New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. , 2001, JAMA.

[13]  R. Smego,et al.  A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. , 2001, Archives of internal medicine.

[14]  B. Dong,et al.  A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  C. Chan,et al.  The safety of i.v. pentamidine administered in an ambulatory setting. , 1996, Chest.

[16]  R. Rodríguez-Roisín,et al.  Prognostic factors influencing the outcome in pneumocystis carinii pneumonia in patients with AIDS. , 1995, Thorax.

[17]  S. Follansbee,et al.  Oral Atovaquone Compared with Intravenous Pentamidine for Pneumocystis carinii Pneumonia in Patients with AIDS , 1994, Annals of Internal Medicine.

[18]  B. Peters,et al.  Adverse Effects of Drugs Used in the Management of Opportunistic Infections Associated with HIV Infection , 1994, Drug safety.

[19]  Allen J. Taylor,et al.  Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. , 1994, Chest.

[20]  A. Gervais,et al.  Higher pentamidine levels in AIDS patients with hypoglycemia and azotemia during treatment of Pneumocystis carinii pneumonia. , 1992, The American review of respiratory disease.

[21]  U. Balslev,et al.  Adverse effects associated with intravenous pentamidine isethionate as treatment of Pneumocystis carinii pneumonia in AIDS patients. , 1992, Danish medical bulletin.

[22]  G. Wormser,et al.  Trimethoprim‐sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial , 1992, AIDS.

[23]  Z. Mohsenifar,et al.  Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS. A randomized trial. , 1990, Annals of internal medicine.

[24]  J. Golden,et al.  Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. , 1990, Annals of internal medicine.

[25]  L. Efferen,et al.  Survival following mechanical ventilation for Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a different perspective. , 1989, The American journal of medicine.

[26]  J. Ruskin,et al.  Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. , 1988, Annals of internal medicine.

[27]  C. Helmick,et al.  Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia. , 1988, JAMA.

[28]  H. Waskin,et al.  Pentamidine and fatal hypoglycemia. , 1987, Annals of internal medicine.

[29]  D. L. Coleman,et al.  Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. , 1986, Annals of internal medicine.

[30]  O. Laskin,et al.  Pentamidine‐induced hypoglycemia in patients with the acquired immune deficiency syndrome , 1986, Clinical pharmacology and therapeutics.

[31]  S. Schwarzmann,et al.  Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. , 1985, Clinical pharmacy.

[32]  H. Haverkos.  Assessment of therapy for pneumocystis carinii pneumonia. PCP Therapy Project Group. , 1984, The American journal of medicine.